Amol Akhade: Oncologists’ preferences following the approval of adjuvant ribociclib
Amol Akhade shared a post on LinkedIn:
”We recently conducted an online poll to gauge oncologists’ preferences following the approval of adjuvant ribociclib.
With two CDK inhibitors now approved for the adjuvant setting in EBC, insights from 173 oncologists shed light on their inclinations:
- 45% favored 2 years of abemaciclib.
- 32% opted to wait for overall survival (OS) benefits.
- 23% leaned towards adjuvant ribociclib for 2 years.
Despite the inherent limitations of an online poll, the emphasis on OS outcomes among oncologists is noteworthy.
The appeal of the shorter duration and improved results offered by adjuvant abemaciclib positions it as a preferred choice for adjuvant therapy.”
Source: Amol Akhade/LinkedIn
Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023